within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR25_LamivudineAndDolutegravir;

model LamivudineAndDolutegravir
  extends Pharmacolibrary.Drugs.ATC.J.J05AR25;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AR25</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lamivudine and dolutegravir is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), while dolutegravir is an integrase strand transfer inhibitor (INSTI). This combination is approved and widely used as a once-daily regimen in adults and adolescents for HIV therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects receiving oral administration of the fixed dose combination (lamivudine 300 mg, dolutegravir 50 mg) as a single dose.</p><h4>References</h4><ol><li><p>Singh, RP, et al., &amp; Wynne, B (2021). Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. <i>Clinical pharmacology in drug development</i> 10(9) 985–993. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.996&quot;>10.1002/cpdd.996</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34265164/&quot;>https://pubmed.ncbi.nlm.nih.gov/34265164</a></p></li><li><p>Dumitrescu, TP, et al., &amp; Adkison, K (2020). Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine. <i>Clinical pharmacology in drug development</i> 9(2) 189–202. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.740&quot;>10.1002/cpdd.740</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31724343/&quot;>https://pubmed.ncbi.nlm.nih.gov/31724343</a></p></li><li><p>Singh, RP, et al., &amp; Buchanan, AM (2022). Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children. <i>The Pediatric infectious disease journal</i> 41(3) 230–237. DOI:<a href=&quot;https://doi.org/10.1097/INF.0000000000003366&quot;>10.1097/INF.0000000000003366</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34817414/&quot;>https://pubmed.ncbi.nlm.nih.gov/34817414</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LamivudineAndDolutegravir;
